A fused heterocyclic compound represented by formula I, pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, Wherein, A 1 is N; A 2 is N; R 2 is -(CR 8 R 9) m NR 5 R 6, -(CR 8 R 9) m NR 7 C(=Y)R 5, -(CR 8 R 9) m NR 7 S 2 R 5, -(CR 8 R 9) m OR 5, -(CR 8 R 9) m S 2 R 5, -(CR 8 R 9) m S 2 NR 5 R 6, -C(OR 5)R 6 R 8, -C(=Y)R 5, -C(=Y)OR 5, -C(=Y)NR 5 R 6, -C(=Y)NR 7 OR 5, -C(=O)NR 7 S 2 R 5, -C(=O)NR 7 (CR 8 R 9) m NR 5 R 6, -NR 7 C(=Y)R 6, -NR 7 C(=Y)OR 6, -NR 7 C(=Y)NR 5 R 6, -NR 7 S 2 R 5, -NR 7 S 2 NR 5 R 6, -SR 5, -S 2 R 5, -S 2 NR 5 R 6, -SC(=Y)R 5, -SC(=Y)OR 5, -O(CR 8 R 9) m NR 5 R 6, a C 1-12 alkyl, a C 2-8 alkenyl, a C 2-8 alkynyl, a C 3-12 carbocyclic group, a C 2-20 heterocyclic group, a C 6-20 aryl or a C 1-20 heteroaryl; or R 2 has a structure selected from the group consisting of (R 3) k represents that the hydrogens attached to the morpholine ring are substituted by 0-k occurrences of R 3, at each occurrence the R 3 is the same or different from each other, and is independently a hydrogen, a deuterium, a halogen, a C 1-6 alkyl, or any two of the R 3 are linked by a single bond, a C 1-6 alkylene or a C 1-6 alkylene substituted by one or two heteroatoms to form a ring structure, the heteroatom is O, N, or S; A is N or CR 4a; D is N; E is N or CR 4e; G is CR 4g; R 4g is -NR 7 S 2 R 5; J is N or CR 4j; R 4a, R 4e and R 4j are each independently a hydrogen, a halogen, -CN, an alkyl, an alkoxy, an alkenyl, an alkynyl, a cycloalkyl, a heterocycloalkyl, -NR 5 R 6, -OR 5, -SR 5, -C R 5, -NR 5 C R 6, -N(C R 6) 2, -NR 5 C NR 5' R 6, -NR 7 S 2 R 5, -C(=O)OR 5 or -C(=O)NR 5 R 6; ring Q is benzene; at each occurrence the R 1 is the same or different from each other, and is each independently a halogen, -CN, an alkyl, an alkoxy, an alkenyl, an alkynyl, a cycloalkyl, a heterocycloalkyl, -NR 5 R 6, -OR 5, -SR 5, -C R 5, -NR 5 C R 6, -N(C R 6) 2, -NR 5 C NR 5' R 6, -NR 7 S 2 R 5, -C(=O)OR 5 or -C(=O)NR 5 R 6; R 5, R 5', R 6, R 7 and R 7' are each independently a hydrogen, a C 1-12 alkyl, -(CH 2) 2-3 NH 2, a C 2-8 alkenyl, a C 2-8 alkynyl, a C 3-12 carbocyclic group, a C 2-20 heterocyclic group, a C 6-20 aryl or a C 1-20 heteroaryl, or R 5, R 6 together with the nitrogen or carbon atoms to which they are directly attached form a heterocyclic ring or a cycloalkyl; or R 7, R 7' together with the nitrogen atom to which R 7 is directly attached form a heterocyclic ring; the heterocyclic ring or the cycloalkyl is optionally substituted by the substituent selected from the group consisting of oxo, -(CH 2) m OR 7, -NR 7 R 7', -CF 3, a halogen, -SO 2 R 7, -C(=O)R 7, -NR 7 C(=Y)R 7', -NR 7 S 2 R 7', -C(=Y)NR 7 R 7', a C 1-12 alkyl, a C 2-8 alkenyl, a C 2-8 alkynyl, a C 3-12 carbocyclic group, a C 2-20 heterocyclic group, a C 6-20 aryl and a C 1-20 heteroaryl; (CR 8 R 9) m represents that 0 to m (CR 8 R 9) are linked with each other, R 8 and R 9 are the substituents attached to the formed carbon chain, wherein each R 8 and R 9 is the same or different from each other, and is each independently a hydrogen, a deuterium, a halogen, -CN, a hydroxyl, an alkoxy, a C 1-12 alkyl, a C 2-12 alkenyl, a C 2-12 alkynyl, a C 3-12 cycloalkyl, a C 6-12 aryl, a 3- to 12-membered heterocycloalkyl or a 5- to 12-membered heteroaryl; or R 8, R 9 together with the atoms to which they are attached form a saturated or partially unsaturated C 3-12 carbon ring or C 2-20 heterocyclic ring; wherein the alkyl, carbocyclic ring and heterocyclic ring can be optionally substituted by the substituent selected from the group consisting of a halogen, a hydroxyl, -CN, -CF 3, -NO 2, oxo, -(CR 8 R 9) m OR 5 and a C 2-20 heterocyclic group; Y is O, S or NR 7; m, k or k1 is independently 0, 1, 2, 3, 4, 5 or 6.